PJT: A Great Business That Nobody Wants Right Now

# PJT: A Great Business That Nobody Wants Right Now

Let's get the absurdity out of the way first, because it's sitting right on top of the pile. Somewhere out there is a forecast predicting PJT Partners will post revenue of $50.4 trillion this year. Not billion. Trillion. That's more than the entire global banking industry makes in a decade. If you're reading a model that tells you to buy, that number is exactly why you shouldn't.

Strip out the noise and what's left is a much cleaner, if less exciting, story.

PJT is the advisory shop that spun out of Blackstone in 2015 and somehow became the most countercyclical play on Wall Street. When deal flow dries up, everyone panics. When credit markets crack and defaults climb, PJT's restructuring arm gets busier than anyone. A 10% jump in corporate default rates adds maybe $200–400 million to the restructuring fee pool, and as a top-three player, PJT captures a disproportionate slice. It's the rare bank that profits from other people's misery.

And the secondaries machine is running hot. The PE secondaries market hit a record $225 billion in volume, PJT flagged expected double-digit growth for 2026, and its Capital Solutions franchise is right in the path of that tailwind. That's not hype — that's a real, structural advantage that most advisory peers can't replicate.

So the business is fine. The problem is the price you have to pay for it.

Here's the tension that keeps this interesting: PJT screens at roughly 20.8x P/E against a 16.6x peer average. Some quotes push the trailing multiple toward 31.5x. Either way, you're paying up. The stock's even above its own five-year median multiple at around 25x. Meanwhile, it's underperformed — down roughly 15% from where we called it a while back, lagging both the broad market and the Capital Markets industry over the trailing year.

Translation: the market is quietly telling you it doesn't believe the premium is justified forever. Deal timelines are murky, mandates-to-revenue conversion may slow, and the restructuring "super-cycle" that's propping up margins is normalizing. Q2 showed revenue up nearly 20% year-over-year, which is genuinely impressive, but operating margin slipped to 21.9% from 23.6% a year earlier. Mild softness, sure. But in a complex that's already priced for perfection, mild softness reads like a warning sign.

Then there's the people who know the business best, and they're leaving the building. Net insider selling of about $1.7 million over three months, no recent buying, Director Emily Rafferty dumping 1,100 shares in August. Not a reason to run. But not a signal you want to ignore when the stock's trading at a premium.

Technically, it's a mess worth watching. The stock sits below its 20-, 50-, and 200-day moving averages — broken short- and medium-term trend, not a healthy coiling pattern. The Relative Strength Index at 32.8 is oversold enough to tempt a bounce, but the model pointing at a ~$163 target has a directional accuracy barely beating a coin flip against the naive baseline. Take the forecast, take it with a grain of salt, and then take the salt.

So where does that leave us?

I'd rather own PJT on weakness than chase it at a premium. The underlying franchise — 20%+ revenue growth, ROE that would make an asset manager blush, free-cash-flow conversion that quietly crushes net income, a balance sheet with a 2.28 quick ratio — is durable. The secondaries and restructuring tailwinds are real, not PowerPoint dreams. But durability at the right price and durability at a premium are two different investments, and right now you're paying for the latter.

The setup is a patience game. Accumulate on weakness, not on optimism. A technical bounce toward the mid-$150s is plausible given how oversold it is, but the models pointing higher are fighting their own track record. Respect the overhead supply sitting up around $172–$195 — that's where frustrated holders and idle shares both wait to unload.

The one genuine forward catalyst on the calendar is the November 3 earnings print. Until then, this is a stock being quietly re-rated lower by a complex that's lost its appetite for expensive quality.

Great business. Unfriendly price. The disciplined move is to let it come to you, and to keep one eye on that $50.4 trillion forecast so you remember who's really doing the talking.